• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    All News #Library
    Biotech

    Satellos Presents at Bloom Burton Healthcare Conference

    GLOBENEWSWIRE

    Satellos To Present At 2026 Muscular Dystrophy Conference

    PHARMIWEB

    Satellos To Participate In Upcoming Investor Conferences

    PHARMIWEB

    Satellos Joins Guggenheim Biotech Summit 2026

    BUSINESSWIRE

    Satellos Completes $57.2M Public Offering In Us And Canada,

    BUSINESSWIRE

    Satellos Prices $50M Public Offering In Us And Canada

    BUSINESSWIRE

    Satellos Launches Public Offering In Canada And Us, Applies

    PHARMIWEB

    Satellos Announces Canada-US IPO, Nasdaq Filing

    PHARMIWEB

    Satellos Appoints Paone as CDO and Head of Regulatory Affairs

    BUSINESSWIRE

    Satellos Plans Share Consolidation For Nasdaq Listing

    BUSINESSWIRE

    Satellos To Participate In December Investor Conferences

    BUSINESSWIRE

    Satellos` Nature Paper Backs Novel DMD Therapy

    BUSINESSWIRE

    Satellos To Participate In November Investor Conferences

    BUSINESSWIRE

    Satellos Announces First Adult Patient Dosed in LT-001

    PHARMIWEB

    Satellos Shows SAT-3247 Safety & Impact In Adult with DMD

    PHARMIWEB

    Satellos To Unveil Sat-3247 Phase 1 Results At 2025 World Muscle

    BUSINESSWIRE

    Satellos Joins Four September Investor Conferences

    BUSINESSWIRE

    Satellos Bioscience Reveals Shareholder Meeting Results

    BUSINESSWIRE

    Satellos Bioscience Shareholders Elect Two New Board Members

    BUSINESSWIRE

    Satellos Reports Q1 2025 Results and Highlights Company Progress

    BUSINESSWIRE

    Satellos Presents Initial Data From SAT-3247 Trial

    BUSINESSWIRE

    Satellos Doses 1st Duchenne Muscular Dystrophy Patient in Trial

    BUSINESSWIRE

    Satellos` SAT-3247 Improves DMD Canines` Strength In Study

    BUSINESSWIRE

    Satellos Doses First Participant in Phase 1 Study of SAT-3247

    BUSINESSWIRE

    Satellos Announces Participation in September 2024 Investor Conferences

    BUSINESSWIRE

    Satellos To Begin Phase 1 Trial With SAT-3247 After Regulatory Approval

    BUSINESSWIRE

    Satellos Announces Q2 2024 Financial Results and Updated Canine Data

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.